Metabolic subtype reveals potential therapeutic vulnerability in acute promyelocytic leukaemia

Clin Transl Med. 2022 Jul;12(7):e964. doi: 10.1002/ctm2.964.

Ji-Yong Sung¹, Woobin Yun², Hyun-Young Kim³, Hee-Jin Kim³, Jong Rak Choi^{1

4}, Sun-Hee Kim³, Chul Won Jung⁵, Seung-Tae Lee^{1

4}

¹ Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, South Korea.
² Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, South Korea.
³ Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
⁴ Dxome Co. Ltd., Seongnam-si, Gyeonggi-do, South Korea.
⁵ Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

No abstract available

Keywords: MAPK expression; acute promyelocytic leukaemia; drug resistance; metabolic reprogramming.

Publication types